Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide

about

Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide

Item

http://www.wikidata.org/entity/Q36232280

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Is dabigatran considered a cos ...... economic evaluations worldwide

@ast

Is dabigatran considered a cos ...... economic evaluations worldwide

@en

type

Item

label

Is dabigatran considered a cos ...... economic evaluations worldwide

@ast

Is dabigatran considered a cos ...... economic evaluations worldwide

@en

prefLabel

Is dabigatran considered a cos ...... economic evaluations worldwide

@ast

Is dabigatran considered a cos ...... economic evaluations worldwide

@en

P1476

Is dabigatran considered a cos ...... economic evaluations worldwide

@en

P2093

Heidi Sjoelund Pedersen

http://www.w3.org/2001/XMLSchema#string

Karin Dam Petersen

http://www.w3.org/2001/XMLSchema#string

Louise Justesen Hesselbjerg

http://www.w3.org/2001/XMLSchema#string

Mikael Bergholdt Asmussen

http://www.w3.org/2001/XMLSchema#string

P2860

Dabigatran versus warfarin in patients with atrial fibrillation

Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial.

Patient time requirements for anticoagulation therapy with warfarin.

The cost-effectiveness of different management strategies for patients on chronic warfarin therapy.

Risk factors for intracerebral hemorrhage in the general population: a systematic review.

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.

Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden.

P304

845-858

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3111/13696998.2013.800523

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23621506

http://www.w3.org/2001/XMLSchema#string

P932

4627374

http://www.w3.org/2001/XMLSchema#string